Health Added 103d ago 8 outlets

Revolution Medicines drug daraxonrasib nearly doubles survival in advanced pancreatic cancer trial.

An experimental pill called daraxonrasib helped patients with advanced pancreatic cancer live longer in a clinical trial of 500 patients. Those taking the drug had a median survival of 13.2 months compared with 6.7 months for chemotherapy recipients. The results were presented Sunday at the American Society for Clinical Oncology meeting in Chicago and published in the New England Journal of Medicine.

Divergence score

8 outlets covered it, splitting into 8 framing camps across 4 bias groups.

8 camps

4 bias groups

Market signalBETA

The spectrum · how 8 outlets placed this story

LeftCenterRight

Washington Times

Reuters

Newsmax

CNN

Le Monde

PBS NewsHour

NY Post

Deutsche Welle

Horizontal = outlet biasColor = this story's framing

Supportive of action

Neutral

Dismissive

Critical

Alarmist

International angle

Widest split · the two outlets furthest apart, and who published first

Furthest apart on this story

Washington Times

Experimental pill promises new hope for deadly pancreatic cancer

patient hope angle · positive

CNN

Experimental pill promises new hope for deadly pancreatic cancer

Hope and clinical milestone · positive

How Washington Times and CNN compare across every story →

First to report

CNNfirst
Newsmax+3.1 h
Reuters+4.1 h
Washington Times+4.5 h
Le Monde+7.5 h
PBS NewsHour+8.8 h
NY Post+52.7 h
Deutsche Welle+197.4 h

By each outlet's earliest publish time in this story. Feeds that index slowly can appear later than they printed.

The split, in one line

Coverage now splits three ways: clinical breakthrough framed as hope or 'grand slam,' realistic limitations emphasizing it's not a cure, and prevention/strategy context, with PBS and DW tempering optimism while NY Post sensationalizes via celebrity case.

How each outlet covered it